Recently, rituximab, an antibody specifically targeting B‐cell depletion initially for lymphoma treatment, has gradually presented potential advantages as an off‐label attempt in treating CIDP or other autoimmune neuropathies caused by nodal–paranodal neurofascin (NF), contactin 1 (CNTN1), and contactin‐associated protein 1 (Caspr1) antibodies.13, 14, 15, 16. The gene discussed is CNTN1; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.